Literature DB >> 10206225

No evidence for linkage between schizophrenia and markers at chromosome 15q13-14.

L Curtis1, J L Blouin, U Radhakrishna, C Gehrig, V K Lasseter, P Wolyniec, G Nestadt, B Dombroski, H H Kazazian, A E Pulver, D Housman, D Bertrand, S E Antonarakis.   

Abstract

Freedman et al. [1997: Proc Natl Acad Sci USA 94:587-592] reported linkage in nine multiplex schizophrenia families to markers on chromosome 15, using impaired neuronal inhibition to repeated auditory stimuli (P50), a neurophysiological deficit associated with schizophrenia, as the phenotype. The highest LOD score obtained (5.3 at theta = 0) was for marker D15S1360 mapped to chromosome 15q13-14, less than 120 kb from the alpha7-nicotinic receptor (CHRNA7) gene. The study also reported a small positive LOD score for D15S1360 when examined for linkage to the schizophrenia phenotype. Following these findings, we examined three polymorphic markers (D15S1360, L76630, and ACTC) on chromosome 15q13-14 near the CHRNA7 gene for linkage to schizophrenia, using 54 pedigrees from an independent study. Alleles for these three markers were genotyped and analyzed using parametric and nonparametric methods. No LOD score above 1.00 was obtained for any marker, and affected sib-pair analysis likewise showed no evidence for linkage. We conclude that in our families the region around the CHRNA7 locus does not contain a major locus for susceptibility to schizophrenia.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10206225     DOI: 10.1002/(sici)1096-8628(19990416)88:2<109::aid-ajmg1>3.0.co;2-3

Source DB:  PubMed          Journal:  Am J Med Genet        ISSN: 0148-7299


  14 in total

1.  Further delineation of the 15q13 microdeletion and duplication syndromes: a clinical spectrum varying from non-pathogenic to a severe outcome.

Authors:  B W M van Bon; H C Mefford; B Menten; D A Koolen; A J Sharp; W M Nillesen; J W Innis; T J L de Ravel; C L Mercer; M Fichera; H Stewart; L E Connell; K Ounap; K Lachlan; B Castle; N Van der Aa; C van Ravenswaaij; M A Nobrega; C Serra-Juhé; I Simonic; N de Leeuw; R Pfundt; E M Bongers; C Baker; P Finnemore; S Huang; V K Maloney; J A Crolla; M van Kalmthout; M Elia; G Vandeweyer; J P Fryns; S Janssens; N Foulds; S Reitano; K Smith; S Parkel; B Loeys; C G Woods; A Oostra; F Speleman; A C Pereira; A Kurg; L Willatt; S J L Knight; J R Vermeesch; C Romano; J C Barber; G Mortier; L A Pérez-Jurado; F Kooy; H G Brunner; E E Eichler; T Kleefstra; B B A de Vries
Journal:  J Med Genet       Date:  2009-04-15       Impact factor: 6.318

Review 2.  Nicotinic mechanisms in the treatment of psychotic disorders: a focus on the α7 nicotinic receptor.

Authors:  Ann Olincy; Robert Freedman
Journal:  Handb Exp Pharmacol       Date:  2012

3.  Sensory gating and alpha-7 nicotinic receptor gene allelic variants in schizoaffective disorder, bipolar type.

Authors:  Laura F Martin; Sherry Leonard; Mei-Hua Hall; Jason R Tregellas; Robert Freedman; Ann Olincy
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2007-07-05       Impact factor: 3.568

Review 4.  Evaluating the role of the alpha-7 nicotinic acetylcholine receptor in the pathophysiology and treatment of schizophrenia.

Authors:  Jared W Young; Mark A Geyer
Journal:  Biochem Pharmacol       Date:  2013-07-12       Impact factor: 5.858

Review 5.  The human CHRNA7 and CHRFAM7A genes: A review of the genetics, regulation, and function.

Authors:  Melissa L Sinkus; Sharon Graw; Robert Freedman; Randal G Ross; Henry A Lester; Sherry Leonard
Journal:  Neuropharmacology       Date:  2015-02-19       Impact factor: 5.250

6.  Splitting schizophrenia: periodic catatonia-susceptibility locus on chromosome 15q15.

Authors:  G Stöber; K Saar; F Rüschendorf; J Meyer; G Nürnberg; S Jatzke; E Franzek; A Reis; K P Lesch; T F Wienker; H Beckmann
Journal:  Am J Hum Genet       Date:  2000-09-19       Impact factor: 11.025

Review 7.  Molecular genetics of schizophrenia: past, present and future.

Authors:  Suman Prasad; Prachi Semwal; Smita Deshpande; Triptish Bhatia; V L Nimgaonkar; B K Thelma
Journal:  J Biosci       Date:  2002-02       Impact factor: 1.826

Review 8.  Treating schizophrenia symptoms with an alpha7 nicotinic agonist, from mice to men.

Authors:  Ann Olincy; Karen E Stevens
Journal:  Biochem Pharmacol       Date:  2007-07-17       Impact factor: 5.858

Review 9.  Alpha-7 nicotinic receptor agonists: potential new candidates for the treatment of schizophrenia.

Authors:  Laura F Martin; William R Kem; Robert Freedman
Journal:  Psychopharmacology (Berl)       Date:  2004-02-19       Impact factor: 4.530

10.  Association between the 2-bp deletion polymorphism in the duplicated version of the alpha7 nicotinic receptor gene and P50 sensory gating.

Authors:  Rachel H Flomen; Madiha Shaikh; Muriel Walshe; Katja Schulze; Mei-Hua Hall; Marco Picchioni; Fruhling Rijsdijk; Timothea Toulopoulou; Eugenia Kravariti; Robin M Murray; Philip Asherson; Andrew J Makoff; Elvira Bramon
Journal:  Eur J Hum Genet       Date:  2012-05-16       Impact factor: 4.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.